DE60015070D1 - Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache - Google Patents

Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache

Info

Publication number
DE60015070D1
DE60015070D1 DE60015070T DE60015070T DE60015070D1 DE 60015070 D1 DE60015070 D1 DE 60015070D1 DE 60015070 T DE60015070 T DE 60015070T DE 60015070 T DE60015070 T DE 60015070T DE 60015070 D1 DE60015070 D1 DE 60015070D1
Authority
DE
Germany
Prior art keywords
convulsive
derivatives
treatment
headache
cluster
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60015070T
Other languages
English (en)
Other versions
DE60015070T2 (de
Inventor
Enrique Carrazana
Steve D Wheeler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Application granted granted Critical
Publication of DE60015070D1 publication Critical patent/DE60015070D1/de
Publication of DE60015070T2 publication Critical patent/DE60015070T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
DE60015070T 1999-01-19 2000-01-13 Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache Expired - Fee Related DE60015070T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11638899P 1999-01-19 1999-01-19
US116388P 1999-01-19
PCT/US2000/000919 WO2000042996A2 (en) 1999-01-19 2000-01-13 Use of anticonvulsant derivatives for treating cluster headaches

Publications (2)

Publication Number Publication Date
DE60015070D1 true DE60015070D1 (de) 2004-11-25
DE60015070T2 DE60015070T2 (de) 2006-01-05

Family

ID=22366884

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60015070T Expired - Fee Related DE60015070T2 (de) 1999-01-19 2000-01-13 Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache

Country Status (24)

Country Link
US (1) US6319903B1 (de)
EP (1) EP1143967B1 (de)
JP (1) JP2002535270A (de)
KR (1) KR100653326B1 (de)
CN (1) CN1182845C (de)
AT (1) ATE279921T1 (de)
AU (1) AU771388B2 (de)
BR (1) BR0008176A (de)
CA (1) CA2359541C (de)
CZ (1) CZ20012620A3 (de)
DE (1) DE60015070T2 (de)
DK (1) DK1143967T3 (de)
ES (1) ES2228465T3 (de)
HU (1) HUP0105154A3 (de)
IL (2) IL144406A0 (de)
MX (1) MXPA01007350A (de)
MY (1) MY121486A (de)
NO (1) NO20013554L (de)
NZ (1) NZ513115A (de)
PT (1) PT1143967E (de)
TR (1) TR200102711T2 (de)
TW (1) TWI248360B (de)
WO (1) WO2000042996A2 (de)
ZA (1) ZA200106786B (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
PL363041A1 (en) * 2000-08-17 2004-11-15 Teva Pharmaceutical Industries, Ltd. Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
WO2004000284A1 (en) 2002-06-21 2003-12-31 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US20030224006A1 (en) 2002-03-01 2003-12-04 Zaworotko Michael J. Multiple-component solid phases containing at least one active pharmaceutical ingredient
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
JP2005518439A (ja) * 2002-02-26 2005-06-23 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 抗痙攣性誘導体と抗片頭痛薬を含んで成る片頭痛治療用共治療薬
AU2003225813A1 (en) * 2002-03-18 2003-10-08 Roger K. Cady Preemptive prophylaxis of migraine
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20040176463A1 (en) * 2003-02-05 2004-09-09 Daniella Licht Immediate release formulation of n-(2-propylpentanoyl)glycinamide
US20040175423A1 (en) * 2003-02-05 2004-09-09 Daniella Licht Sustained release formulation of N- (2-propylpentanoyl) glycinamide and related compounds
US6949518B1 (en) 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
CA2578407A1 (en) * 2004-08-24 2006-03-02 Janssen Pharmaceutica N.V. Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
US20110117070A1 (en) * 2005-04-19 2011-05-19 Aurora Sheena K Compositions and methods for treating headache
US20060233892A1 (en) * 2005-04-19 2006-10-19 Curt Hendrix Topiramate compositions for treatment of headache
JP2008545650A (ja) * 2005-05-20 2008-12-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ スルファミド誘導体の製造方法
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
AR058389A1 (es) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
WO2007137167A2 (en) 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
US9744137B2 (en) 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
ES2312308T3 (es) 2006-11-17 2013-03-26 Supernus Pharmaceuticals, Inc. Formulaciones de liberación sostenida de topiramato
ES2645719T3 (es) * 2006-12-04 2017-12-07 Supernus Pharmaceuticals, Inc. Formulaciones de topiramato de liberación inmediata mejoradas
US20090076128A1 (en) * 2007-09-15 2009-03-19 Protia Llc Deuterium-enriched topiramate
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) * 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
AU2009271362B2 (en) 2008-06-23 2014-03-13 Janssen Pharmaceutica Nv Crystalline form of (2s)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
WO2013139292A1 (zh) 2012-03-23 2013-09-26 中国人民解放军军事医学科学院毒物药物研究所 一种含辛弗林和托吡酯的联合产品
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
CN102579367B (zh) 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2020104837A1 (en) 2018-11-21 2020-05-28 Rosemont Pharmaceuticals Limited Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US5998380A (en) * 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
AP1513A (en) * 1996-10-08 2005-12-12 Ortho Mcneil Pharm Inc Anti-convulsant derivatives useful in treating neuropathic pain.

Also Published As

Publication number Publication date
CN1182845C (zh) 2005-01-05
ZA200106786B (en) 2002-11-18
DE60015070T2 (de) 2006-01-05
PT1143967E (pt) 2005-01-31
HUP0105154A3 (en) 2004-10-28
CN1352555A (zh) 2002-06-05
NO20013554D0 (no) 2001-07-18
KR100653326B1 (ko) 2006-12-04
EP1143967A2 (de) 2001-10-17
MXPA01007350A (es) 2003-06-06
MY121486A (en) 2006-01-28
IL144406A0 (en) 2002-05-23
IL144406A (en) 2006-08-20
TWI248360B (en) 2006-02-01
HUP0105154A2 (hu) 2002-04-29
DK1143967T3 (da) 2005-01-10
JP2002535270A (ja) 2002-10-22
WO2000042996A3 (en) 2000-12-07
CA2359541A1 (en) 2000-07-27
KR20010101595A (ko) 2001-11-14
US6319903B1 (en) 2001-11-20
NO20013554L (no) 2001-07-18
EP1143967B1 (de) 2004-10-20
AU2726800A (en) 2000-08-07
CZ20012620A3 (cs) 2002-09-11
ES2228465T3 (es) 2005-04-16
CA2359541C (en) 2005-06-21
NZ513115A (en) 2004-11-26
AU771388B2 (en) 2004-03-18
WO2000042996A2 (en) 2000-07-27
BR0008176A (pt) 2001-11-06
ATE279921T1 (de) 2004-11-15
TR200102711T2 (tr) 2001-12-21

Similar Documents

Publication Publication Date Title
DE60015070D1 (de) Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
ATE305307T1 (de) Reboxetin zur behandlung von migränekopfschmerzen
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69732152D1 (de) Vorrichtung zur Behandlung von Kopfschmerzen
DE69528475T2 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE69936890D1 (de) Vorrichtung zur Behandlung von Ischämie
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60014928D1 (de) Retinoide zur behandlung von emphysem
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
DE69825286D1 (de) Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen
TR200103125T2 (tr) Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
DE69915690D1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
DE69827387D1 (de) Verwendung von pramipexol zur behandlung von restless-legs-syndrom
DE60009315D1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
DE69806062D1 (de) Kombinationstherapie zur behandlung von aids
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
DE69409961T2 (de) Triarylethylenderivate zur therapeutischen verwendung
DE60000658D1 (de) Zusammensetzung zur behandlung von psoriasis
DE59904564D1 (de) Verwendung von acetylcholinesterase-inhibitoren zur behandlung von delirien
BR0008791A (pt) Derivados anticonvulsivos, úteis no tratamento de tremor essencial
DE69706195T2 (de) Antikonvulsive derivate zur behandlung von psoriasis
DE69924385D1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
DE69711422D1 (de) Verwendung von (r)-verapamil als medizin zur behandlung von angina
ATE294590T1 (de) Verwendung von interleukin-11 zur behandlung von hämoragischem schock

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: BOEHMERT & BOEHMERT, 28209 BREMEN

8339 Ceased/non-payment of the annual fee